GVHD characteristics at second-line treatment (N = 312)
| Characteristic . | No. (%) . |
|---|---|
| Median time from initial treatment to second-line treatment, range, mo | 6.3 (0.2-61) |
| Reason for second-line treatment | |
| Progression | 230 (74) |
| Lack of improvement | 82 (26) |
| Sites involved | |
| Skin | 226 (72) |
| Eyes | 120 (38) |
| Mouth | 221 (71) |
| Liver | 91 (29) |
| Gastrointestinal tract | |
| Upper only | 46 (15) |
| Any lower | 47 (15) |
| Lung | 35 (11) |
| Joint or fascia | 73 (23) |
| Genital tract | 31 (10) |
| Serosa | 4 (1) |
| No. of sites involved | |
| 1 or 2 | 127 (41) |
| 3 | 94 (30) |
| 4 or more | 91 (29) |
| NIH global score | |
| Mild | 26 (8) |
| Moderate | 154 (50) |
| Severe | 128 (42) |
| Not available | 4 |
| Platelet count | |
| <100 000/μL | 54 (18) |
| ≥100 000/μL | 250 (82) |
| Not available | 8 |
| Serum total bilirubin | |
| >2 mg/dL | 23 (7) |
| ≤2 mg/dL | 286 (93) |
| Not available | 3 |
| Prednisone-equivalent steroid dose immediately before second-line treatment | |
| None | 46 (15) |
| <0.5 mg/kg per day | 140 (45) |
| 0.5-1.0 mg/kg per day | 72 (23) |
| ≥1.0 mg/kg per day | 52 (17) |
| Not available | 2 |
| Second-line treatment | |
| Mycophenolate mofetil | 95 (30) |
| Tacrolimus | 63 (20) |
| Sirolimus | 57 (18) |
| Extracorporeal photopheresis | 23 (7) |
| Cyclosporine | 17 (5) |
| Methotrexate | 10 (3) |
| Other single agents | 24 (8) |
| Multiple agents | 23 (7) |
| Characteristic . | No. (%) . |
|---|---|
| Median time from initial treatment to second-line treatment, range, mo | 6.3 (0.2-61) |
| Reason for second-line treatment | |
| Progression | 230 (74) |
| Lack of improvement | 82 (26) |
| Sites involved | |
| Skin | 226 (72) |
| Eyes | 120 (38) |
| Mouth | 221 (71) |
| Liver | 91 (29) |
| Gastrointestinal tract | |
| Upper only | 46 (15) |
| Any lower | 47 (15) |
| Lung | 35 (11) |
| Joint or fascia | 73 (23) |
| Genital tract | 31 (10) |
| Serosa | 4 (1) |
| No. of sites involved | |
| 1 or 2 | 127 (41) |
| 3 | 94 (30) |
| 4 or more | 91 (29) |
| NIH global score | |
| Mild | 26 (8) |
| Moderate | 154 (50) |
| Severe | 128 (42) |
| Not available | 4 |
| Platelet count | |
| <100 000/μL | 54 (18) |
| ≥100 000/μL | 250 (82) |
| Not available | 8 |
| Serum total bilirubin | |
| >2 mg/dL | 23 (7) |
| ≤2 mg/dL | 286 (93) |
| Not available | 3 |
| Prednisone-equivalent steroid dose immediately before second-line treatment | |
| None | 46 (15) |
| <0.5 mg/kg per day | 140 (45) |
| 0.5-1.0 mg/kg per day | 72 (23) |
| ≥1.0 mg/kg per day | 52 (17) |
| Not available | 2 |
| Second-line treatment | |
| Mycophenolate mofetil | 95 (30) |
| Tacrolimus | 63 (20) |
| Sirolimus | 57 (18) |
| Extracorporeal photopheresis | 23 (7) |
| Cyclosporine | 17 (5) |
| Methotrexate | 10 (3) |
| Other single agents | 24 (8) |
| Multiple agents | 23 (7) |